OptiBiotix Health (LON:OPTI – Get Free Report) released its quarterly earnings results on Thursday. The company reported GBX (3.84) EPS for the quarter, Digital Look Earnings reports. OptiBiotix Health had a negative return on equity of 2.27% and a negative net margin of 16.59%.The business had revenue of GBX 117 million for the quarter.
OptiBiotix Health Stock Performance
Shares of OPTI opened at GBX 6.05 on Friday. The stock has a 50 day simple moving average of GBX 5.31 and a 200 day simple moving average of GBX 6.35. OptiBiotix Health has a 52-week low of GBX 4.50 and a 52-week high of GBX 15. The firm has a market capitalization of £6.25 million, a PE ratio of -201.67 and a beta of 1.71.
Insider Activity
In other OptiBiotix Health news, insider David Blain acquired 158,965 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average cost of GBX 6 per share, for a total transaction of £9,537.90. Corporate insiders own 26.82% of the company’s stock.
About OptiBiotix Health
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products.
Read More
- Five stocks we like better than OptiBiotix Health
- Wall Street Is Starting to Talk About Tesla’s Endgame
- Meta’s Manus Mess: Why China Blocked the Deal and What It Means
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
Receive News & Ratings for OptiBiotix Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiBiotix Health and related companies with MarketBeat.com's FREE daily email newsletter.
